Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia: Randomised Control

NCT06187285 is registered in ClinicalTrials.gov with Medanta, The Medicity, India as lead sponsor.

NCT NCT06187285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06187285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia: Randomised Control
Lead sponsor
Medanta, The Medicity, India
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2024
Completion date
June 1, 2025
Enrollment
220 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes